Skip to content
value.today

Axion BioSystems, Inc.

🇺🇸 Atlanta, Georgia, USABiotechnologyFounded 2007

Formerly Axion BioSystems LLC

Total raised
$21 M
5 rounds on record
Latest round
$8 M
Sep 2018
First round on record
Apr 2009
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Axion BioSystems, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2018$8 MNo. 5$2 to $10 million

Axion BioSystems, Inc.: Raise no. 5, Sep 2018

Investors in this round

31 investors had bought by the notice of Oct 5, 2018: 31 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James J. Ross · Executive Officer, Director · Chief Technical Officer
  • Thomas J. O'Brien · Executive Officer, Director · President and Chief Executive Officer
  • David J. Gibson · Director
  • Glenn J. Epstein · Director
  • Jay J. Teich · Director
  • Michelle J. Jarrard · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas O'Brien, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 5, 2018. Read the notice at the SEC.

equitySEC
May 2016$6 MNo. 4$2 to $10 million

Axion BioSystems, Inc.: Raise no. 4, May 2016

Investors in this round

16 investors had bought by the notice of May 17, 2016: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James J. Ross · Executive Officer, Director · Director, President and Chief Technical Officer
  • Thomas J. O'Brien · Executive Officer, Director · Director, Chief Executive Officer
  • David J. Gibson · Director
  • Glenn J. Epstein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas O'Brien, President and chief executive officer. Source: SEC Form D, newest notice filed May 17, 2016. Read the notice at the SEC.

equity, optionsSEC
Apr 2012$3 MNo. 3$2 to $10 million

Axion BioSystems, Inc.: Raise no. 3, Apr 2012

Investors in this round

17 investors had bought by the notice of May 9, 2012: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $4 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James J. Ross · Executive Officer, Director · Director and Vice President
  • Julian A. Bragg · Executive Officer · Vice President
  • Stephen J. DeWeerth · Executive Officer · Vice President
  • Swaminathan J. Rajaraman · Executive Officer · Vice President
  • Thomas J. O'Brien · Executive Officer, Director · Director, President and Chief Executive Officer
  • Glenn A. Epstein · Director
  • Mark J. Allen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas O'Brien, President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 9, 2012. Read the notice at the SEC.

equity, optionsSEC
Jul 2010$2 MNo. 2$2 to $10 million

Axion BioSystems, Inc.: Raise no. 2, Jul 2010

Investors in this round

10 investors had bought by the notice of Jul 28, 2010: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edgar J. Brown · Executive Officer · Vice President
  • James J. Ross · Executive Officer, Director · Director and Vice President
  • Julian A. Bragg · Executive Officer · Vice President
  • Stephen J. DeWeerth · Executive Officer · Vice President
  • Swaminathan J. Rajaraman · Executive Officer · Vice President
  • Thomas J. O'Brien · Executive Officer, Director · Director, President and Chief Executive Officer
  • Glenn A. Epstein · Director
  • Mark J. Allen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas O'Brien, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 28, 2010. Read the notice at the SEC.

equity, optionsSEC
Apr 2009$1 MNo. 1Under $2 million

Axion BioSystems, Inc.: Raise no. 1, Apr 2009

Investors in this round

19 investors had bought by the notice of Apr 30, 2009: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • Edgar Brown · Executive Officer · Vice President
  • James Ross · Executive Officer, Director · Director and Vice President
  • Julian A. Bragg · Executive Officer · Vice President
  • Stephen DeWeerth · Executive Officer · Vice President
  • Swaminathan Rajaraman · Executive Officer · Vice President
  • Thomas J. O'Brien · Executive Officer, Director · Director, President and Chief Executive Officer
  • Greg Dane · Director
  • Mark Allen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas J. O'Brien, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 30, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Axion BioSystems, Inc. had revenue between $5 million and $25 million when it filed its newest notice of a funding round (Oct 2018).

    SEC Form D (revenue range) · Oct 2018

  • Revenue range over time, as stated in its notices: revenue of up to $1 million in 2010; revenue between $1 million and $5 million in 2012; revenue between $5 million and $25 million in 2016; revenue between $5 million and $25 million in 2018.

    SEC Form D (revenue range) · Oct 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2018

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Axion BioSystems, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 31 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Axion BioSystems, Inc.
NameRoleNamed in
James J. RossChief Technical OfficerOct 2018
Thomas J. O'BrienPresident and Chief Executive OfficerOct 2018
Julian A. BraggVice PresidentMay 2012
Stephen J. DeWeerthVice PresidentMay 2012
Swaminathan J. RajaramanVice PresidentMay 2012
Edgar J. BrownVice PresidentJul 2010
Edgar BrownVice PresidentApr 2009
James RossDirector and Vice PresidentApr 2009
Stephen DeWeerthVice PresidentApr 2009
Swaminathan RajaramanVice PresidentApr 2009
David J. GibsonDirectorOct 2018
Glenn J. EpsteinDirectorOct 2018
James J. RossChief Technical OfficerOct 2018
Jay J. TeichDirectorOct 2018
Michelle J. JarrardDirectorOct 2018
Thomas J. O'BrienPresident and Chief Executive OfficerOct 2018
Glenn A. EpsteinDirectorMay 2012
Mark J. AllenDirectorMay 2012
Greg DaneDirectorApr 2009
James RossDirector and Vice PresidentApr 2009
Mark AllenDirectorApr 2009